Clinical trial Recruiting at 1 site Phase 3 Interventional Ages 8 to 17

Ketotifen treatment for children with functional dyspepsia and duodenal eosinophilia

Official title: Double-blind, Placebo-controlled, Cross-over Trial of Ketotifen in Children and Adolescents With Functional Dyspepsia in Association With Duodenal Eosinophilia

Run by Children's Mercy Hospital Kansas City · NCT02484248 · Data updated 2026-11-12

This study is testing if ketotifen can help children aged 8 to 17 with stomach issues and high eosinophils feel better when other treatments haven't worked.

More Functional Dyspepsia trials

Quick facts

PhasePhase 3
Study typeInterventional
Ages8 Years to 17 Years
SexAll
Enrollment40 (estimated)
SponsorChildren's Mercy Hospital Kansas City
Academic / other
Locations1 site (Kansas City, Missouri)
StatusRecruiting
StartedAugust 2015
Main results expectedApril 1, 2027
Study endsApril 1, 2027
Registry record updatedJanuary 9, 2026
Trial IDNCT02484248 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are children aged 8 to 17 with a diagnosis of functional dyspepsia and evidence of duodenal eosinophilia who have not adequately responded to acid-reduction therapy.

Probably not a fit

Patients who have previously been treated with ketotifen or have certain chronic medical conditions may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of ketotifen, a mast cell stabilizer, in treating children aged 8 to 17 who suffer from functional dyspepsia associated with duodenal eosinophilia. The study is designed as a double-blind, placebo-controlled, cross-over trial, where participants will receive either ketotifen or a placebo in two phases. The primary goal is to assess the symptomatic response to ketotifen compared to placebo in children who have not adequately responded to standard acid-reduction therapy. Participants will undergo multiple clinic visits and phone interviews throughout the study duration to monitor their symptoms and overall health.

Why it matters

Potential benefit: If successful, this treatment could provide significant relief for children suffering from functional dyspepsia who have not responded to conventional therapies.

How similar studies have gone: While there have been no prior studies specifically on ketotifen for functional dyspepsia, mast cell stabilizers have shown benefits in related conditions, suggesting potential for success.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. between the ages of 8 and 17 years, inclusive
2. abdominal pain of at least 8 weeks duration and fulfilling symptom-based criteria for functional dyspepsia(5);
3. previous endoscopy with biopsies demonstrating \>20 eosinophils/high powered field on duodenal mucosal biopsies;
4. previous treatment with acid-reduction therapy and montelukast with a level 3 (as defined below)or lesser response;
5. evidence of written parental permission (consent) and subject assent;
6. Negative pregnancy screening for females of child bearing potential.

Exclusion Criteria:

1. previous treatment with ketotifen;
2. treatment with oral corticosteroids or oral cromolyn sodium in the 6 months prior to enrollment;
3. any prior history of diabetes mellitus, cancer, chronic cardiac disease, respiratory disease, or renal disease requiring routine medical care;
4. Pregnant/planning to become pregnant;
5. Post-menarche females unwilling to use highly-efficacious contraception to prevent pregnancy;
6. Epilepsy or history of seizures;
7. Liver disease or elevation of liver enzymes;
8. Use of oral hypoglycemic medications, antipsychotics, benzodiazepines, tricyclic antidepressants, barbiturates, or opioids;
9. Allergy to ketotifen or other products in capsule
10. Refusal of Urine pregnancy test in post-menarchal females.

Where it's running

  • The Children's Mercy Hospital
    Kansas City, Missouri, United States
    Recruiting

Study contacts

  • Principal investigator: Craig A Friesen, MD — Children's Mercy Hospital Kansas City
  • Study coordinator: Craig A Friesen, M.D.
  • Email: cfriesen@cmh.edu
  • Phone: 816-234-3066

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.